Q-omics provides the consensus-scored DENND3 profile across patient tissues and cancer cell-line models. DENND3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DENND3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, DENND3 protein abundance shows 37,201 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where DENND3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND3 survival associations across molecular data types. DENND3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND3 RNA expression–survival associations across cancer types. High DENND3 expression shows unfavorable associations in UVM, LGG, LUSC and ACC, but favorable associations in SKCM and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DENND3 RNA expression.
This table summarizes DENND3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DENND3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND3 shows lower tumor expression in LUAD, THCA and LUSC and higher tumor expression in HNSC, KIRC and KIRP. The HNSC box plot shows higher DENND3 RNA expression in tumor versus normal tissue (log2 FC = +1.196, t-test p < 0.001).
This table shows molecular features associated with DENND3 in patient tissues and cancer cell lines. In patient samples, DENND3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
